Trucchio sees 48-week data as key for Phase 3 progress, while William Blair questions drug’s impact on fibrosis and weight loss at 24 weeks.
Latest Ratings for ALT
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 2021 | B. Riley Securities | Maintains | Buy | |
| Jun 2021 | JMP Securities | Maintains | Market Outperform | |
| Jun 2021 | HC Wainwright & Co. | Maintains | Buy |
